Guangzhou biosimilar developer with multiple approved biosimilars including a bevacizumab copy sold in China and abroad.
Guangzhou biosimilar developer with multiple approved biosimilars including a bevacizumab copy sold in China and abroad.
Earns partly from selling its own biosimilars in China, and partly from licence fees, milestone payments and supply income from overseas partners that handle registration and sales in their regions. Biosimilars are copies of biologic drugs, which are made in living cells and so cannot be copied exactly like pills.
In one line: A Chinese Coherus BioSciences (biosimilars).
Moat: narrow (regulatory licence, scale). Approved biosimilar manufacturing plus global partner licensing deals are costly and slow to duplicate.
Headquarters: Guangzhou, China · Founded: 2003 · Employees: 1,426
Size Bio-Thera Solutions (688177.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $929M, the 2302nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.03 on 18 Nov 2026.
Performance Over six months the shares fell 23.2%, against -16.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 24.1% over the last twelve months (peer median +2.4%); the operating margin is -44.2% (peer median 8.8%).
Valuation It trades at 6.5× enterprise value to sales against a peer median of 3.8× (5th most expensive of 18).
Capital Return on invested capital runs 47.5 points below its cost of capital (8.1% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.05B | CN¥933M | CN¥741M | CN¥703M | CN¥454M |
| Revenue growth | — | +26% | +5% | +55% | — |
| Gross profit | CN¥874M | CN¥668M | CN¥467M | CN¥467M | CN¥233M |
| EBITDA | n/a | -CN¥303M | -CN¥449M | -CN¥380M | -CN¥441M |
| Net income | -CN¥441M | -CN¥332M | -CN¥510M | -CN¥395M | -CN¥480M |
| Free cash flow | -CN¥255M | -CN¥202M | -CN¥202M | -CN¥686M | -CN¥646M |
| Capital expenditure | CN¥279M | CN¥122M | CN¥127M | CN¥262M | CN¥259M |
| Total debt | CN¥971M | CN¥686M | CN¥629M | CN¥483M | CN¥9.51M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Bio-Thera Solutions 688177.SS | $929M | -23% | +24% | -44% | 6.5× | n/a |
| Shanghai Henlius Biotech 2696.HK | $3.05B | -39% | +33% | 12% | 3.3× | 14.1% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 4.2× | 7.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688177.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | -9.1% | 5th lowest of 21 |
| 6-month return | -23.2% | -16.9% | 9th lowest of 20 |
| Distance from 52-week high | -44.5% | -48.9% | 10th highest of 21 |
| Revenue growth (TTM) | +24.1% | +2.4% | 4th highest of 18 |
| Operating margin | -44.2% | 8.8% | 4th lowest of 18 |
| EV / Sales | 6.5× | 3.8× | 5th most expensive of 18 |
| ROIC minus cost of capital | -47.5 pp | -1.1 pp | lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 5.4× | 17.7% | +27.3% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 6.3× | 5.6% | +9.3% |